Novartis reports data at EBCC-9 for secondary survival endpoint of Afinitor ... MarketWatch Basel, March 19, 2014 - Results from the secondary endpoint of the Phase III BOLERO-2 (Breast cancer trials of OraL EveROlimus-2) study of Afinitor(R) (everolimus) trial were presented today at the 9th European Breast Cancer Conference (EBCC-9) in ... |
